<DOC>
	<DOCNO>NCT00023413</DOCNO>
	<brief_summary>The aim trial study efavirenz-rifabutin interaction . Thus , trial enroll patient HIV tuberculosis co-infections receive rifabutin-based regimen plan begin antiretroviral regimen contain efavirenz dose 600 mg daily . Enrollment TB Trials Consortium Study 23 requirement participation study . Primary Objective : To compare pharmacokinetics rifabutin 600 mg twice week combination efavirenz 600 mg daily pharmacokinetics rifabutin 300 mg twice week without efavirenz .</brief_summary>
	<brief_title>TBTC Study 23C : Pharmacokinetics Intermittent Rifabutin Isoniazid With Daily Efavirenz</brief_title>
	<detailed_description />
	<mesh_term>Infection</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Isoniazid</mesh_term>
	<mesh_term>Rifabutin</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>Patients HIV tuberculosis coinfections receive rifabutinbased regimen plan begin antiretroviral regimen contain efavirenz dose 600 mg daily .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2012</verification_date>
	<keyword>tuberculosis</keyword>
	<keyword>TB</keyword>
</DOC>